Skip to main content

Table 1 Previous studies

From: Double-labelling immunohistochemistry for MGMT and a “cocktail” of non-tumourous elements is a reliable, quick and easy technique for inferring methylation status in glioblastomas and other primary brain tumours

Author and year Tumour type Cut off value for IHC Low MGMT protein expression predictive of: MGMT IHC compared to molecular gold standard Molecular test Correlation between IHC and molecular test
Progression free survival (PFS) Overall survival (OS)
Nakasu et al. 2004 [7] 69 high-grade gliomas (grades III and IV) 10% - Yes No - -
Brell et al. 2005 [11] 93 anaplastic gliomas: 75 AAs and 18 with oligodendroglial component 5% No Yes Yes MS-PCR No
Chinot et al. 2007 [21] 28 GBMs 35% Yes Yes No - -
Capper et al. 2008 [22] 75 primary GBMs 15% Yes – median survival No - -
Preusser et al. 2008 [6] 164 GBMs 10% - No Yes MS-PCR Poor agreement
Rodriguez et al. 2008 [23] 50 GBMs 10% No No Yes MS-PCR No
Karayan-Tapon et al. 2010 [24] 81 GBMs 15% No No Yes MS-PCR -
SQ-PCR No
Pyrosequencing Yes
Q-RT-PCR Yes
Quillien et al. 2012 [5] 100 GBMs 23% Yes Yes No - -
  1. The table shows previous studies where MGMT IHC has been performed. The cut-off value was the percentage of MGMT-positive tumour cell nuclei (assessed by eye). The correlation of IHC with progression-free survival (PFS) and overall survival (OS) and comparison with a molecular gold standard (where applied) are also shown.
  2. Abbreviations: AA anaplastic astrocytoma, GBM glioblastoma multiforme, MS-PCR methylation-specific polymerase chain reaction, Q-RT-PCR quantitative real-time polymerase chain reaction, SQ-PCR semi-quantitative polymerase chain reaction.